These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12520558)

  • 1. Some fundamental issues with non-inferiority testing in active controlled trials.
    James Hung HM; Wang SJ; Tsong Y; Lawrence J; O'Neil RT
    Stat Med; 2003 Jan; 22(2):213-25. PubMed ID: 12520558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACT method for non-inferiority testing in active controlled trials.
    Wang SJ; Hung HM
    Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and analysis of non-inferiority mortality trials in oncology.
    Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
    Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
    Schwartz TA; Denne JS
    Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On non-inferiority analysis based on delta-method confidence intervals.
    Rothmann MD; Tsou HH
    J Biopharm Stat; 2003 Aug; 13(3):565-83. PubMed ID: 12921402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of delta noninferiority margin and dependency of the noninferiority trials.
    Tsong Y; Zhang J; Levenson M
    J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
    Wang YC; Chen G; Chi GY
    J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strength of evidence of non-inferiority trials-The adjustment of the type I error rate in non-inferiority trials with the synthesis method.
    Kang SH; Tsong Y
    Stat Med; 2010 Jun; 29(14):1477-87. PubMed ID: 20535762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials.
    Wang SJ; Hung HM; Tsong Y; Cui L
    Stat Med; 2001 Jul; 20(13):1903-12. PubMed ID: 11427948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL; Shih MC; Zhu G
    Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
    Hirotsu C
    Pharm Stat; 2007; 6(3):193-203. PubMed ID: 17879327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A covariate-adjustment regression model approach to noninferiority margin definition.
    Nie L; Soon G
    Stat Med; 2010 May; 29(10):1107-13. PubMed ID: 20209669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
    Hung HM; Wang SJ; O'Neill R
    Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.
    Pigeot I; Schäfer J; Röhmel J; Hauschke D
    Stat Med; 2003 Mar; 22(6):883-99. PubMed ID: 12627407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On non-inferiority margin and statistical tests in active control trials.
    Chow SC; Shao J
    Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous test for superiority and noninferiority hypotheses in active-controlled clinical trials.
    Tsong Y; Zhang J
    J Biopharm Stat; 2007; 17(2):247-57. PubMed ID: 17365221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.